Brainstorm Cell Therapeutics Inc (BCLI)

Etorro trading 970x250

About Brainstorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer’s disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. Address: 1325 Avenue of Americas, New York, NY, United States, 10019

Brainstorm Cell Therapeutics Inc News and around…

Latest news about Brainstorm Cell Therapeutics Inc (BCLI) common stock and company :

Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
05 Jan, 2022 FinancialContent
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
05 Jan, 2022 FinancialContent

Gainers Sensus Healthcare (NASDAQ:SRTS) shares moved upwards by 18.6% to $8.1 during Wednesday's pre-market session. ...

BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022
04 Jan, 2022 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D. MHSc, President and Chief Medical Officer of Brainstorm Cell Therapeutics, will provide a corporate and clinical overview at Biotech Showcase™ 2022, to be held virtually January 10-12 and 17-18, 2022. The presentation will be pre-recorded and available on-demand for registered attendees of the conference.

FDA Authorizes Further NurOwn® Dosing Under Expanded Access Program
27 Dec, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced plans for a dosing extension of NurOwn® for participants who completed the Expanded Access Protocol (EAP). The U.S. Food and Drug Administration (FDA) recommended that BrainStorm submit an EAP protocol amendment to provide additional dosing for these participants. Under the original EAP protocol, participants who had completed the Phase 3 NurOwn trial and wh

50 Biggest Movers From Yesterday
15 Dec, 2021 FinancialContent

Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 143.8% to settle at $12.19 on Tuesday after the company priced its IPO at ...

34 Stocks Moving In Tuesday's Mid-Day Session
14 Dec, 2021 FinancialContent

Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.8% to $0.3830. Exicure’s Audit Committee recently concluded that Grant Corbett ...

20 Stocks Moving in Tuesday's Pre-Market Session
14 Dec, 2021 FinancialContent

Gainers MIND Technology, Inc. (NASDAQ: MIND) rose 37.2% to $1.88 in pre-market trading after the company reported it entered into ...

BCLI: Phase 3 ALS Results Published in Muscle and Nerve…
13 Dec, 2021 Yahoo! Finance

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Phase 3 ALS Data Published in Muscle and Nerve On December 13, 2021, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced the publication of results from the Phase 3 clinical trial of NurOwn in patients with amyotrophic lateral sclerosis (ALS). The publication, entitled “A Randomized Placebo-Controlled Phase

BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve
13 Dec, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publication of Phase 3 clinical data in Muscle and Nerve. The paper, entitled "A Randomized Placebo-Controlled Phase 3 Study of Mesenchymal Stem Cells Induced to Secrete High Levels of Neurotrophic Factors in Amyotrophic Lateral Sclerosis," can be found here.

BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing
07 Dec, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, and Catalent (NYSE: CTLT), a global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that the technology transfer for NurOwn® manufacturing at Catalent's facility has been finalized. NurOwn is BrainStorm's autologous cellular therapy bein

BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn® at the International Symposium on ALS/MND
02 Dec, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that biomarker data on NurOwn® will be presented at the 32nd International Symposium on ALS/MND, to be held virtually 7-10 December 2021. The presentation "NurOwn targets multiple disease pathways in ALS Phase 3 Trial" will be delivered by Robert Brown, M.D., Director of the Program in Neurotherapeutics at the University of Massachusetts Medical School, and

BrainStorm Cell ALS Candidate Shows Benefit In Patients With Less Severe Disease
29 Nov, 2021 FinancialContent

BrainStorm Cell Therapeutics Inc(NASDAQ: BCLI) has announced the presentation ofnew analyses from the Phase 3 ...

BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium
29 Nov, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium. The presentation, which will be delivered Tomorrow by Dr. Jonathan Katz, a co-principal investigator on the trial and Chair of the Neurology Department and Director of the Forbes Norris ALS Clinic at the California Pacific Medical Center, showed th

68 Biggest Movers From Wednesday
26 Nov, 2021 FinancialContent

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced ...

Interesting BCLI Put And Call Options For May 2022
24 Nov, 2021 FinancialContent

Investors in Brainstorm Cell Therapeutics Inc (BCLI) saw new options begin trading this week, for the May 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 177 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

BCLI: Biomarkers Predict Response in ALS Phase 3 Trial…
17 Nov, 2021 Yahoo! Finance

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update New Biomarker Data from Phase 3 ALS Trial On October 6, 2021, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced the presentation of an abstract containing new data from the Phase 3 trial in amyotrophic lateral sclerosis (ALS) showing that changes in specific biomarkers were correlated with the primary

BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
15 Nov, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced financial results for the quarter ended September 30, 2021, and provided a corporate update.

BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
08 Nov, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced executive appointments as the company prepares for future growth. Sidney A. Spector, MD, PhD, was named Senior Vice President Global Strategy and Medical Affairs and Kim Thacker, MD, was named Senior Vice President, Medical Affairs and Clinical Innovation. BrainStorm also has expanded the responsibilities of Stacy Lindborg, PhD, Executive Vice President, app

Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors
28 Oct, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Menghis Bairu, MD, to the company's Board of Directors. The appointment becomes effective on October 28, 20221.

BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate Update
25 Oct, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on November 15, 2021.

BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting
18 Oct, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Therapeutic Benefits of MSC-NTF (NurOwn®) Exosomes in Acute Lung Injury Models" at the NYSCF 2021 VIRTUAL Meeting, being held on October 19-20, 2021. The poster will be presented tomorrow, October 19, at 3:45 – 5:00pm Eastern Time.

Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
14 Oct, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multicenter, open label clinical trial of NurOwn® in progressive multiple sclerosis. The study, "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis," will be delivered in an oral presentation today at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Scl

BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021
06 Oct, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial" will be presented as a scientific poster at the fully digital 2021 Northeast Amyotrophic Lateral Sclerosis Consortium® (NEALS) conference. The presentation will be delivered by James Berry, M.D. MPH, Winthrop Family Scholar in ALS Sciences, Di

BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa
04 Oct, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conference October 12-14, and October 19-20, 2021.

BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS
01 Oct, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis" will be presented in an oral presentation at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The presentation will be delivered by Jeffrey Cohen, M.D. Direct

What Kind Of Investors Own Most Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)?
24 Sep, 2021 Yahoo! Finance

If you want to know who really controls Brainstorm Cell Therapeutics Inc. ( NASDAQ:BCLI ), then you'll have to look at...

The Math Shows FDM Can Go To $76
24 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $75.53 per unit.

BCLI: Weighing Options for How Best to Advance NurOwn® in ALS…
06 Aug, 2021 Yahoo! Finance

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Determining the Best Path Forward for NurOwn® in ALS BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) has completed a Phase 3 clinical trial for NurOwn as a treatment for amyotrophic lateral sclerosis (ALS) and in November 2020 announced topline results showing that the trial did not reach statistical significance

BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
05 Aug, 2021 Yahoo! Finance

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended June 30, 2021 and provided a corporate update.

63 Biggest Movers From Friday
02 Aug, 2021 FinancialContent

Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has ...

Brainstorm Cell Therapeutics Inc (BCLI) is a NASDAQ Common Stock listed in , ,

970x250